Product Description
Avigen was developing av-650, an oral sodium channel inhibitor, for the treatment of Muscle Spasticity (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00531466)
Mechanisms of Action: Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avigen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Spinal Cord Injuries|Muscle Spasticity
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AV650-012 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-21 |
Treatments |
|
| AV650-019 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-21 |
Treatments |
|
| AV650-014 | P2 |
Terminated |
Spinal Cord Injuries|Muscle Spasticity |
2008-11-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|